ClinicalTrials.gg
RecruitingNCT07112339Updated Aug 11, 2026

A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes

A Phase 4 interventional study of Insulin icodec and Basal insulin analogues in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Recruiting at 75 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
586
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 — 2 open to participants now, 2 under way, none of them phase 3. insulin icodec · Diabetes Mellitus, Type 2.

Planned enrollment
5th of 27
586 · median 84
Started
2025
the only one that year
Phase 4
2 of 27
2 open now
Registered
26th of 27
by date
Lead sponsor
26 of 27
Novo Nordisk A/S

Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, this one is the 5th largest by planned enrollment, is the only one that started in 2025, is one of 2 in phase 4, and was the 26th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About insulin icodec

insulin icodec: first FDA approval 2026 (AWIQLI FLEXTOUCH), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study compares insulin icodec, taken once a week, with other basal insulins, taken once a day, in people with type 2 diabetes.The purpose of this study is to see how well the approved injectable weekly insulin icodec maintains blood sugar levels when compared to approved and available daily injectable basal insulins in people with type 2 diabetes. The participants will either be prescribed weekly insulin icodec or a daily basal insulin (insulin glargine, insulin detemir or insulin degludec) based on current standards for the treatment of type 2 diabetes. The study will last for about 13 months.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with T2D greater than or equal to (≥) 180 days prior to the day of screening.
  • Treatment with any of the following non-insulin glucose-lowering medication(s) or combination regimen(s) at the time of screening:

Metformin, Sulfonylureas, Meglitinides (glinides), dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, Thiazolidinediones, Alpha-glucosidase inhibitors, Oral combination products (for the allowed individual oral antidiabetic drugs), Oral or injectable glucagon-like peptide-1 (GLP-1) receptor agonists and Injectable dual glucose-dependent insulinotropic polypeptides (GIP) and GLP-1 receptor agonist.

  • Need of intensification with basal insulin, as indicated at the discretion of the investigator.
  • Recorded value ≥7% within the last 90 days prior to randomization.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to study intervention(s) or related products.
  • Previous participation in this study. Participation is defined as signed .
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using adequate method.
  • Participation (i.e., received any study intervention) in any interventional clinical study within 90 days before screening.
  • Any disorder which in the investigator's opinion might jeopardize participant's safety.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
586 participants (estimated)

Study arms

  • Experimental
    Insulin icodec

    Participants will receive subcutaneous (s.c) injection of once weekly insulin icodec.

    Drug: Insulin icodec

  • Active comparator
    Basal insulin analogues

    Participants will receive once daily s.c. injection of basal insulin analogues.

    Drug: Basal insulin analogues

Interventions

  • Insulin icodec will be administered as subcutaneous injection.

  • DrugBasal insulin analogues

    Basal insulin analogues will be administered as subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Change in glycated haemoglobin (HbA1c)

    Measured as %-point.

    Time frame: From baseline week 0 to week 52

Secondary outcomes

  1. Adelphi Adherence Questionnaire (ADAQ©)

    Measured as Score. The ADAQ© score is calculated as the mean of 11 individual items, each rated on a scale from 0 to 4. To obtain the mean score, at least 8 of these items must be answered. A lower score indicates greater adherence.

    Time frame: At week 52

  2. Change in Diabetes Treatment Satisfaction Questionnaire- status version(DTSQs) total treatment satisfaction

    Measured as Score of 0-36. DTSQs score ranges from 0 to 36, based on 6 items that are each rated on a scale of 0 to 6. A higher score reflects greater satisfaction with the treatment received.

    Time frame: From baseline week 0 to week 52

  3. Treatment Related Impact Measure for Diabetes (TRIM-D) compliance domain

    Measured as Score of 4-20.The score ranges from 4 to 20, based on 4 items rated on a scale of 1 to 5. This score is then transformed to a 0-100 scale, where higher scores indicate better compliance.

    Time frame: At week 52

  4. Treatment Related Impact Measure for Diabetes (TRIM-D) treatment burden domain

    Measured as Score of 6-30. The score ranges from 6 to 30, derived from 6 items each rated on a scale of 1 to 5. This score is then transformed to a 0-100 scale, where higher scores indicate less treatment burden.

    Time frame: At week 52

  5. Number of severe hypoglycaemic episodes (level 3)

    Measured as Number of episodes.

    Time frame: From baseline week 0 to week 52

  6. Mean weekly basal insulin dose

    Measures in Units.

    Time frame: From week 50 to week 52

  7. Participant achieved individualised HbA1c target

    Reported as Yes or No.

    Time frame: At week 52

07

Study locations

58 of 75 sites recruiting
  • Centricity Research Calgary Endocrinology
    Calgary, Alberta T2H 2G4, Canada
    Recruiting
  • Alta Clinical Research at Hermitage Medicentre
    Edmonton, Alberta T5A 4L8, Canada
    Recruiting
  • Fraser Clinical Trials Inc.
    New Westminster, British Columbia V3L 3W4, Canada
    Recruiting
  • Winnipeg Clinic
    Winnipeg, Manitoba R3C 0N2, Canada
    Recruiting
  • G.A. Research Associates Ltd.
    Moncton, New Brunswick E1G 1A7, Canada
    Recruiting
  • Centricity Research Brampton Endocrinology
    Brampton, Ontario L6S 0C6, Canada
    Recruiting
  • Centricity Clinical Research Burlington
    Burlington, Ontario L7M 4Y1, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Centricity Research Vaughn Endocrinology
    Concord, Ontario L4K 4M2, Canada
    Recruiting
  • Medical Trust Clinics, Inc.
    Courtice, Ontario L1E2J5, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Centricity Research Etobicoke Endocrinology
    Etobicoke, Ontario M9R 4E1, Canada
    Recruiting
  • Janik Research
    Greater Sudbury, Ontario P3C 1SB, Canada
    Recruiting
  • Hamilton Medical Research Group
    Hamilton, Ontario L8M 1K7, Canada
    Recruiting
  • St. Josephs Health Care
    London, Ontario N6A 4V2, Canada
    Recruiting
  • Western Univ. Cnt for Studies in Fam Med
    London, Ontario N6G 2M1, Canada
    Recruiting
  • Malton Medical Clinic
    Mississauga, Ontario L4V 1P1, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Centricity Research Ottawa LMC
    Nepean, Ontario K2J 0V2, Canada
    Recruiting
  • The Ottawa Hospital_Riverside
    Ottawa, Ontario K1H7W9, Canada
    Not yet recruiting
  • Bluewater Clin Res Group Inc
    Sarnia, Ontario N7T 4X3, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Sewa Ram Singal Medicine Professional Corp
    Toronto, Ontario M3N 2V6, Canada
    Recruiting
  • Centricity Research Toronto
    Toronto, Ontario M4G 3E8, Canada
    Recruiting
  • Centricity Research Toronto Manna Multispec
    Toronto, Ontario M9W 4L6, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Diex Recherche Joliette
    Joliette, Quebec J6E 6A9, Canada
    Recruiting
  • Alpha Recherche Clinique - Clinique de Levis
    Lévis, Quebec G6V 0C9, Canada
    Recruiting
  • Centricity Research Mirabel
    Mirabel, Quebec J7J 2K8, Canada
    Recruiting
  • Centre hospitalier de l'Universite de Montreal
    Montreal, Quebec H2W 1R7, Canada
    Not yet recruiting
  • McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
    Not yet recruiting
  • Applied Medical Informatics Research
    Montreal, Quebec H4A 3T2, Canada
    Recruiting
  • Clinique Endocrinologie OASIS.
    Montreal, Quebec H4J 1E3, Canada
    Recruiting
  • Centricity Res Pointe-Claire
    Pointe-Claire, Quebec H9R 4S3, Canada
    Recruiting
  • ALPHA Recherche Clinique
    Québec, Quebec G3K 2P8, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Diex Recherche Sherbrooke
    Sherbrooke, Quebec J1E 0N8, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Centre de Recherche Saint-Louis
    Sherbrooke, Quebec J1G 1X9, Canada
    Recruiting
  • Ctr de Med Metab de Lanaudiere
    Terrebonne, Quebec J6X 4P7, Canada
    Recruiting
  • Diex Recherche Trois-Rivieres
    Trois-Rivières, Quebec G9A 4P3, Canada
    Recruiting
  • Diex Recherche Victoriaville
    Victoriaville, Quebec G6P 3Z8, Canada
    Recruiting
  • Recherche Clinique Sigma Inc.
    Québec, G1G 5X1, Canada
    Recruiting
  • Diex Recherche Quebec
    Québec, G1V 4T3, Canada
    Recruiting
  • Centre de Recherche Saint-Louis
    Québec, G1W 4R4, Canada
    Recruiting
  • Alpha Recherche Clinique - Lebourgneuf
    Québec, G2J 0C4, Canada
    Recruiting
  • Versdias - Diabetologikum Amberg
    Amberg, Bavaria 92224, Germany
    Recruiting
  • Diabetespraxis Mergentheim
    Bad Mergentheim, 97980, Germany
    Recruiting
  • Praxis Dr. Stephan Scharla
    Bad Reichenhall, 83435, Germany
    Not yet recruiting
  • Medizinisches Versorgungszentrum Am Bahnhof Spandau GbR
    Berlin, 13597, Germany
    Recruiting
  • Studiengesellschaft Dres. Könemann/Steinmann GbR
    Bünde, 32257, Germany
    Recruiting
  • Diabetologische Schwerpunktpraxis Daaden
    Daaden, 57567, Germany
    Recruiting
  • Diabeteszentrum-Do Dres. K U. Ch. Busch GbR
    Dortmund, 44137, Germany
    Recruiting
  • Studienzentrum Dr. Faulmann GbR Dresden
    Dresden, 01279, Germany
    Recruiting
  • MVZ Hausärzte Großenbaum GmbH Duisburg
    Duisburg, 47269, Germany
    Recruiting
  • Praxis für Diabetologie, Angiologie und Innere Medizin Eisenach
    Eisenach, 99817, Germany
    Completed

    Not enrolling at this site — choose another above.

  • MVZ Contilia GmbH
    Essen, 45219, Germany
    Recruiting
  • Praxis am Markt Dr. Becker
    Essen, 45355, Germany
    Recruiting
  • MVZ im Altstadt-Carree Fulda GmbH - Zentrum für klinische Studien
    Fulda, 36037, Germany
    Recruiting
  • Diabetes-Zentrum-Wilhelmsburg GbR
    Hamburg, 21109, Germany
    Recruiting
  • Mesut Durmaz, Hof
    Hof, 95030, Germany
    Recruiting
  • Praxisgemeinschaft Jerichow
    Jerichow, 39319, Germany
    Recruiting
  • Familienmedizinisches Zentrum Radowsky
    Leipzig, 04179, Germany
    Recruiting
  • Praxis Am Oberen Tor - Dr. Simon-Wagner
    Lichtenfels, 96215, Germany
    Recruiting
  • Diabeteszentrum Ludwigsburg
    Ludwigsburg, 71634, Germany
    Recruiting
  • Institut für Diabetesforschung Osnabrück
    Osnabrück, 49080, Germany
    Recruiting
  • ceda - Centrum für Diabetologie und Allgemeinmedizin Pohlheim
    Pohlheim, 35415, Germany
    Not yet recruiting
  • Hegau-Bodensee-Klinikum Singen
    Singen, 78224, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Dr. Schmidt-Reinwald Astrid, Trier
    Trier, 54292, Germany
    Recruiting
  • A.O.U. Consorziale Policlinico di Bari
    Bari, BA 70124, Italy
    Not yet recruiting
  • Azienda Ospedaliero Universitaria Renato Dulbecco - Mater Domini
    Catanzaro, Calabria 881100, Italy
    Recruiting
  • AOU Vanvitelli - DAI Medicina Interna, Geriatria e Neurologia - U.O.C. Endocrinologia e Malattie del Metabolismo
    Naples, Campania 80138, Italy
    Not yet recruiting
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Centro malattie endocrine e metaboliche
    Rome, Lazio 00168, Italy
    Recruiting
  • ASST Fatebenefratelli Ospedale Luigi Sacco - Malattie Endocrine e Diabetologia
    Milan, Lombardy 20157, Italy
    Recruiting
  • DAI Scienze Mediche - UOSD Diabetologia
    Messina, Sicily 98124, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone - Presidio Villa Belmonte
    Palermo, Sicily 90142, Italy
    Recruiting
  • AST Fermo - Ospedale Murri - Unità Operativa di Diabetologia e Endocrinologia
    Fermo, The Marches 63900, Italy
    Recruiting
  • Azienda Ospedaliero Universitaria Careggi - Diabetologia e malattie del metabolismo
    Florence, Tuscany 50134, Italy
    Recruiting
  • Azienda Ospedaliera di Perugia;Ospedale S. Maria della Misericordia
    Perugia, Umbria 06129, Italy
    Recruiting
  • Università degli studi G. D'Annunzio Chieti Pescara - CAST
    Chieti Scalo, 66100, Italy
    Recruiting
  • AUSL Romagna - Medicine Specialistiche Ravenna - UO Servizio di Diabetologia di Ravenna
    Ravenna, 48121, Italy
    Not yet recruiting
  • Azienda Ospealiero Universitaria Policlinico Umberto I
    Roma, 00161, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Mar 2028, 31 months after the start.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's planned 31 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2025
First posted
Aug 8, 2025
StartActual
Aug 15, 2025
Primary completionEst.
Mar 23, 2028
CompletionEst.
Mar 23, 2028
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07112339
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Aug 15, 2025
Primary completion
Mar 23, 2028 (estimated)
Completion
Mar 23, 2028 (estimated)
Last update
Aug 11, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin icodec

Start the discussion